Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKT137831 for diabetic kidney disease in adults with type 1 diabetes and persistent albuminuria
ACTRN12617001187336Phase 2Terminated
- Sponsor
- Baker Heart and Diabetes Institute
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing GKT137831 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Mean urine albumin-to-creatinine ratio at 48 weeks adjusted for baseline. Started Dec 2017; status: terminated.
02
Drugs
setanaxib
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on ACTRN12617001187336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001187336.